Moderna, Sinovac Biotech gear up for final phase trials
- 4 years ago
Coronavirus (Covid-19) vaccines status check: Moderna, Sinovac Biotech gear up for final phase trials
Even as Covid-19 cases across the world cross 7.41 million, including 4,18,000 deaths, two of the leading names in the development of a vaccine — US firm Moderna Inc and China’s Sinovac Biotech Ltd — have made discernible progress with their experimental candidate.
On the other hand, Chinese firm Sinovac Biotech’s inactivated vaccine — CoronaVac — is also set to enter phase 3 clinical trials in Brazil.
Moderna vaccine status
Sinovac Biotech vaccine status
Oxford-AstraZeneca vaccine status
The AZD1222 vaccine, being jointly developed by British pharma giant AstraZeneca and Oxford University, is presently undergoing phase II trials with 10,000 volunteers. The late-stage trials of the vaccine will be conducted in Brazil.
The Cambridge-based firm has signed deals to produce 400 million doses for the US and 100 million for the UK if it is successful in human trials.
Johnson & Johnso
Even as Covid-19 cases across the world cross 7.41 million, including 4,18,000 deaths, two of the leading names in the development of a vaccine — US firm Moderna Inc and China’s Sinovac Biotech Ltd — have made discernible progress with their experimental candidate.
On the other hand, Chinese firm Sinovac Biotech’s inactivated vaccine — CoronaVac — is also set to enter phase 3 clinical trials in Brazil.
Moderna vaccine status
Sinovac Biotech vaccine status
Oxford-AstraZeneca vaccine status
The AZD1222 vaccine, being jointly developed by British pharma giant AstraZeneca and Oxford University, is presently undergoing phase II trials with 10,000 volunteers. The late-stage trials of the vaccine will be conducted in Brazil.
The Cambridge-based firm has signed deals to produce 400 million doses for the US and 100 million for the UK if it is successful in human trials.
Johnson & Johnso